147 related articles for article (PubMed ID: 33743183)
1. Introduction and clearance of beta-glucan in the downstream processing of monoclonal antibodies.
Kluters S; Steinhauser K; Pfänder R; Studts J
Biotechnol Prog; 2021 Jul; 37(4):e3149. PubMed ID: 33743183
[TBL] [Abstract][Full Text] [Related]
2. Control of leached beta-glucan levels from depth filters by an improved depth filtration flush strategy.
Holstein M; Jang D; Urrea C; Botta LS; Grimm W; Ghose S; Li ZJ
Biotechnol Prog; 2021 Jan; 37(1):e3086. PubMed ID: 33016571
[TBL] [Abstract][Full Text] [Related]
3. Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
Miao F; Velayudhan A; DiBella E; Shervin J; Felo M; Teeters M; Alred P
Biotechnol Prog; 2009; 25(4):964-72. PubMed ID: 19569193
[TBL] [Abstract][Full Text] [Related]
4. Efficiency of ultrafiltration/diafiltration in removing organic and elemental process equipment related leachables from biological therapeutics.
Sun B; Hadidi M; Santiago Nuñez J; Song B; Tumambac GE; Wong K; Kalinowski G; Hathcock JJ
Biotechnol Prog; 2024; 40(1):e3400. PubMed ID: 37964726
[TBL] [Abstract][Full Text] [Related]
5. Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.
Vigor K; Emerson J; Scott R; Cheek J; Barton C; Bax HJ; Josephs DH; Karagiannis SN; Spicer JF; Lentfer H
Biotechnol Prog; 2016 Nov; 32(6):1494-1502. PubMed ID: 27604040
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic model of pH and excipient concentration during ultrafiltration and diafiltration processes of therapeutic antibodies.
Ladwig JE; Zhu X; Rolandi P; Hart R; Robinson J; Rydholm A
Biotechnol Prog; 2020 Sep; 36(5):e2993. PubMed ID: 32185869
[TBL] [Abstract][Full Text] [Related]
7. Multipronged approach to managing beta-glucan contaminants in the downstream process: control of raw materials and filtration with charge-modified nylon 6,6 membrane filters.
Gefroh E; Hewig A; Vedantham G; McClure M; Krivosheyeva A; Lajmi A; Lu Y
Biotechnol Prog; 2013; 29(3):672-80. PubMed ID: 23596143
[TBL] [Abstract][Full Text] [Related]
8. A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.
Abel J; Kosky A; Ball N; Bacon H; Kaushik R; Kleemann GR
J Pharm Sci; 2018 May; 107(5):1296-1303. PubMed ID: 29339134
[TBL] [Abstract][Full Text] [Related]
9. A mechanistic model to account for the Donnan and volume exclusion effects in ultrafiltration/diafiltration process of protein formulations.
Yu Z; Moomaw JF; Thyagarajapuram NR; Geng SB; Bent CJ; Tang Y
Biotechnol Prog; 2021 Mar; 37(2):e3106. PubMed ID: 33289341
[TBL] [Abstract][Full Text] [Related]
10. Experimental proof of contamination of blood components by (1-->3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process.
Nagasawa K; Yano T; Kitabayashi G; Morimoto H; Yamada Y; Ohata A; Usami M; Horiuchi T
J Artif Organs; 2003; 6(1):49-54. PubMed ID: 14598125
[TBL] [Abstract][Full Text] [Related]
11. Positive (1-->3)-beta-D-glucan in blood components and release of (1-->3)-beta-D-glucan from depth-type membrane filters for blood processing.
Usami M; Ohata A; Horiuchi T; Nagasawa K; Wakabayashi T; Tanaka S
Transfusion; 2002 Sep; 42(9):1189-95. PubMed ID: 12430677
[TBL] [Abstract][Full Text] [Related]
12. Clearance of solvents and small molecule impurities in antibody drug conjugates via ultrafiltration and diafiltration operation.
Gates TJ; Lyu YF; Fang X; Liao X
Biotechnol Prog; 2020 Jan; 36(1):e2923. PubMed ID: 31587515
[TBL] [Abstract][Full Text] [Related]
13. Adapting virus filtration to enable intensified and continuous monoclonal antibody processing.
Bohonak DM; Mehta U; Weiss ER; Voyta G
Biotechnol Prog; 2021 Mar; 37(2):e3088. PubMed ID: 33016523
[TBL] [Abstract][Full Text] [Related]
14. Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.
Teeters M; Bezila D; Benner T; Alfonso P; Alred P
Biotechnol Bioeng; 2011 Jun; 108(6):1338-46. PubMed ID: 21328314
[TBL] [Abstract][Full Text] [Related]
15. Streamlining process characterization efforts using the high throughput ambr® crossflow system for ultrafiltration and diafiltration processing of monoclonal antibodies.
Fernandez-Cerezo L; Benner SW; Pollard JM
Biotechnol Prog; 2021 May; 37(3):e3118. PubMed ID: 33369289
[TBL] [Abstract][Full Text] [Related]
16. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.
Cheung NK; Modak S; Vickers A; Knuckles B
Cancer Immunol Immunother; 2002 Nov; 51(10):557-64. PubMed ID: 12384807
[TBL] [Abstract][Full Text] [Related]
17. Assessing the impact of sanitization methods for regenerated cellulose ultrafiltration/diafiltration membrane on membrane integrity and protein quality.
Cong X; Chen W; Wang L; Wan Y
Biotechnol Prog; 2023; 39(6):e3377. PubMed ID: 37470193
[TBL] [Abstract][Full Text] [Related]
18. Effects of Impurities from Sugar Excipient on Filtrate Flux during Ultrafiltration and Diafiltration Process.
Lee J; Na J; Baek Y
Membranes (Basel); 2021 Oct; 11(10):. PubMed ID: 34677543
[TBL] [Abstract][Full Text] [Related]
19. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
20. A (1-->3,1-->4)-beta-glucan-specific monoclonal antibody and its use in the quantitation and immunocytochemical location of (1-->3,1-->4)-beta-glucans.
Meikle PJ; Hoogenraad NJ; Bonig I; Clarke AE; Stone BA
Plant J; 1994 Jan; 5(1):1-9. PubMed ID: 8130794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
